Atossa Therapeutics
ATOS
14 hedge funds and large institutions have $649K invested in Atossa Therapeutics in 2019 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 4 closing their positions.
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 4
0.59% less ownership
Funds ownership: 3.38% → 2.79% (-0.59%)
41% less capital inflows, than outflows
Capital inflows: $285K | Capital outflows: $480K
50% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$137K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$114K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$27.5K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$6.01K |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$801 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIP
Ahrens Investment Partners
Lafayette,
Louisiana
|
-$240K |
| 2 |
VF
Virtu Financial
New York
|
-$128K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$92K |
| 4 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$13.3K |
| 5 |
Barclays
London,
United Kingdom
|
-$4.49K |
ATOS Hedge Fund Activity: Q2 2019 in Review
14 of the 4,626 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2019, worth a combined $649K — down 15% from $765K a quarter earlier.
Fund positioning in ATOS was balanced in Q2 2019: 4 funds opened new positions, 4 closed out, 2 added to existing stakes and 4 trimmed.
The largest buyer was Vanguard Group, adding an estimated $137K. The largest seller was Ahrens Investment Partners, cutting an estimated $240K.
- 14 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2019, unchanged from Q1 2019.
- Funds reported $649K of Atossa Therapeutics stock for Q2 2019, down 15% quarter-over-quarter.
- 4 funds opened new Atossa Therapeutics positions in Q2 2019 and 4 closed out, a net change of 0 holders.
- The largest Atossa Therapeutics buyer in Q2 2019 was Vanguard Group, an estimated $137K added.
- The largest Atossa Therapeutics seller in Q2 2019 was Ahrens Investment Partners, an estimated $240K sold.
Based on aggregated 13F filings for Q2 2019.